阴性乳腺癌-话题@MedSci

#阴性乳腺癌#

226篇内容 | 3200人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2048100, encodeId=8f2e2048100a3, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=J Immunother Cancer：浙大黄建团队提出三阴性乳腺癌肺转移免疫学新机制及其干预策略, objectType=article, longId=265021, objectId=bd0926502166, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bd0926502166, replyNumber=0, likeNumber=73, createdTime=2022-10-06, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bd0926502166, moduleTitle=J Immunother Cancer：浙大黄建团队提出三阴性乳腺癌肺转移免疫学新机制及其干预策略, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bd0926502166)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048091, encodeId=550020480919b, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=ASCO 2021：摘要概览与展望19 |乳腺癌研究概览（三阴性乳腺癌专栏）, objectType=article, longId=212197, objectId=060821219ee9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=060821219ee9, replyNumber=0, likeNumber=64, createdTime=2021-07-21, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=060821219ee9, moduleTitle=ASCO 2021：摘要概览与展望19 |乳腺癌研究概览（三阴性乳腺癌专栏）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=060821219ee9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048088, encodeId=5a3920480881d, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=三阴性乳腺癌何时才能产出里程碑式治疗药物？, objectType=article, longId=209768, objectId=27d1209e681f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=27d1209e681f, replyNumber=0, likeNumber=67, createdTime=2021-04-11, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=27d1209e681f, moduleTitle=三阴性乳腺癌何时才能产出里程碑式治疗药物？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=27d1209e681f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048097, encodeId=fe87204809ef2, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=Cancer Cell：张泽民团队等揭示抗PD-L1免疫治疗联合化疗在三阴性乳腺癌中的作用机制, objectType=article, longId=218860, objectId=c4e02188600e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c4e02188600e, replyNumber=0, likeNumber=68, createdTime=2022-07-10, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c4e02188600e, moduleTitle=Cancer Cell：张泽民团队等揭示抗PD-L1免疫治疗联合化疗在三阴性乳腺癌中的作用机制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c4e02188600e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048098, encodeId=3021204809887, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=Cell Metab：“饿死”肿瘤的想法真的可实现了？科学家发现模拟禁食饮食可以阻止三阴性乳腺癌和癌症干细胞逃逸！, objectType=article, longId=219988, objectId=909321998894, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=909321998894, replyNumber=0, likeNumber=0, createdTime=2022-01-26, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=909321998894, moduleTitle=Cell Metab：“饿死”肿瘤的想法真的可实现了？科学家发现模拟禁食饮食可以阻止三阴性乳腺癌和癌症干细胞逃逸！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=909321998894)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048094, encodeId=665e2048094c5, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=Ann Oncol:紫杉醇联合或不联合atezolizumab一线治疗不可切除、局部晚期或转移性三阴性乳腺癌的疗效: IMpassion131初次分析, objectType=article, longId=213741, objectId=328f213e41bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=328f213e41bd, replyNumber=0, likeNumber=57, createdTime=2022-05-14, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=328f213e41bd, moduleTitle=Ann Oncol:紫杉醇联合或不联合atezolizumab一线治疗不可切除、局部晚期或转移性三阴性乳腺癌的疗效: IMpassion131初次分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=328f213e41bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048085, encodeId=114920480855b, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=Clin Cancer Res：艾立布林联合帕博利珠单抗对转移性三阴性乳腺癌有效, objectType=article, longId=208835, objectId=da3a20883514, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=da3a20883514, replyNumber=0, likeNumber=72, createdTime=2021-10-28, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=da3a20883514, moduleTitle=Clin Cancer Res：艾立布林联合帕博利珠单抗对转移性三阴性乳腺癌有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=da3a20883514)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048080, encodeId=f823204808044, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=伦敦癌症研究所（ICR）：palbociclib有望治疗三阴性乳腺癌, objectType=article, longId=206378, objectId=97c82063e85a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=97c82063e85a, replyNumber=0, likeNumber=65, createdTime=2021-02-05, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=97c82063e85a, moduleTitle=伦敦癌症研究所（ICR）：palbociclib有望治疗三阴性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=97c82063e85a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048087, encodeId=80f9204808e18, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=FDA批准吉利德的Trodelvy治疗三阴性乳腺癌, objectType=article, longId=209690, objectId=6a6f209690af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6a6f209690af, replyNumber=0, likeNumber=55, createdTime=2021-06-19, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6a6f209690af, moduleTitle=FDA批准吉利德的Trodelvy治疗三阴性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6a6f209690af)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048096, encodeId=be782048096bc, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=欧盟人用药品委员会 (CHMP) 对sacituzumab govitecan单药治疗三阴性乳腺癌 (TNBC) 持积极意见, objectType=article, longId=218739, objectId=cba7218e390b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cba7218e390b, replyNumber=0, likeNumber=118, createdTime=2021-10-21, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cba7218e390b, moduleTitle=欧盟人用药品委员会 (CHMP) 对sacituzumab govitecan单药治疗三阴性乳腺癌 (TNBC) 持积极意见, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cba7218e390b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048084, encodeId=979d204808475, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=AACR 2021：NX-1607治疗结直肠癌和三阴性乳腺癌，临床前研究效果显著, objectType=article, longId=208270, objectId=d4122082e0e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d4122082e0e1, replyNumber=0, likeNumber=64, createdTime=2021-08-08, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d4122082e0e1, moduleTitle=AACR 2021：NX-1607治疗结直肠癌和三阴性乳腺癌，临床前研究效果显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d4122082e0e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048089, encodeId=35b9204808934, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=NEJM：ADC药物Sacituzumab govitecan一线治疗转移性三阴性乳腺癌, objectType=article, longId=210410, objectId=eb7421041030, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eb7421041030, replyNumber=0, likeNumber=62, createdTime=2021-07-15, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eb7421041030, moduleTitle=NEJM：ADC药物Sacituzumab govitecan一线治疗转移性三阴性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eb7421041030)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048077, encodeId=c49120480e7e7, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=JAMA：卡培他滨维持治疗对早期三阴性乳腺癌疗效观察的影响, objectType=article, longId=204500, objectId=b002204500d3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b002204500d3, replyNumber=0, likeNumber=71, createdTime=2021-08-11, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b002204500d3, moduleTitle=JAMA：卡培他滨维持治疗对早期三阴性乳腺癌疗效观察的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b002204500d3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048078, encodeId=a75e20480e839, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=Eur J Cancer：BRCA1/2突变对三阴性乳腺癌新辅助化疗时发生严重血液毒性风险的影响, objectType=article, longId=205690, objectId=826020569015, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=826020569015, replyNumber=0, likeNumber=61, createdTime=2021-10-01, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=826020569015, moduleTitle=Eur J Cancer：BRCA1/2突变对三阴性乳腺癌新辅助化疗时发生严重血液毒性风险的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=826020569015)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048093, encodeId=c2b9204809387, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=Ann Oncol: atezolizumab联合白蛋白结合型紫杉醇一线治疗不可切除、局部晚期或转移性三阴性乳腺癌的疗效: IMpassion130最终总生存分析, objectType=article, longId=213736, objectId=41a6213e36ec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=41a6213e36ec, replyNumber=0, likeNumber=106, createdTime=2022-01-13, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=41a6213e36ec, moduleTitle=Ann Oncol: atezolizumab联合白蛋白结合型紫杉醇一线治疗不可切除、局部晚期或转移性三阴性乳腺癌的疗效: IMpassion130最终总生存分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=41a6213e36ec)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048082, encodeId=774b204808266, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=默沙东Keytruda治疗三阴性乳腺癌扩大标签申请未能获得FDA支持, objectType=article, longId=207159, objectId=3efa20e159a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3efa20e159a6, replyNumber=0, likeNumber=75, createdTime=2021-08-28, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3efa20e159a6, moduleTitle=默沙东Keytruda治疗三阴性乳腺癌扩大标签申请未能获得FDA支持, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3efa20e159a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048090, encodeId=2078204809083, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=ASCO 2021：摘要概览与展望10 |乳腺癌研究概览（三阴性乳腺癌专栏）, objectType=article, longId=211913, objectId=94fc21191398, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=94fc21191398, replyNumber=0, likeNumber=0, createdTime=2021-10-26, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=94fc21191398, moduleTitle=ASCO 2021：摘要概览与展望10 |乳腺癌研究概览（三阴性乳腺癌专栏）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=94fc21191398)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048072, encodeId=70ac20480e222, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=Cell Death Dis：FBI-1通过miR-30c/PXR通路增强三阴性乳腺癌的耐药性, objectType=article, longId=202310, objectId=31a8202310bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=31a8202310bc, replyNumber=0, likeNumber=72, createdTime=2021-09-19, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=31a8202310bc, moduleTitle=Cell Death Dis：FBI-1通过miR-30c/PXR通路增强三阴性乳腺癌的耐药性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=31a8202310bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048069, encodeId=e1e02048069ed, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=三阴性乳腺癌：令人闻风丧胆的肿瘤！3种新疗法或将提高生存率, objectType=article, longId=200565, objectId=d66d2005656f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d66d2005656f, replyNumber=0, likeNumber=73, createdTime=2021-05-10, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d66d2005656f, moduleTitle=三阴性乳腺癌：令人闻风丧胆的肿瘤！3种新疗法或将提高生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d66d2005656f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048071, encodeId=07bf20480e1ea, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=CSCO 2020丨袁芃教授：三阴性乳腺癌（TNBC）治疗未来之路----精准检测和新的靶点, objectType=article, longId=201053, objectId=669b2010537d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=669b2010537d, replyNumber=0, likeNumber=48, createdTime=2021-04-20, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=669b2010537d, moduleTitle=CSCO 2020丨袁芃教授：三阴性乳腺癌（TNBC）治疗未来之路----精准检测和新的靶点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=669b2010537d)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

阴性乳腺癌

2020-05-29

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

J Immunother Cancer：浙大黄建团队提出三阴性乳腺癌肺转移免疫学新机制及其干预策略

2022-10-06

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

ASCO 2021：摘要概览与展望19 |乳腺癌研究概览（三阴性乳腺癌专栏）

2021-07-21

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

三阴性乳腺癌何时才能产出里程碑式治疗药物？

2021-04-11

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

Cancer Cell：张泽民团队等揭示抗PD-L1免疫治疗联合化疗在三阴性乳腺癌中的作用机制

2022-07-10

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

Cell Metab：“饿死”肿瘤的想法真的可实现了？科学家发现模拟禁食饮食可以阻止三阴性乳腺癌和癌症干细胞逃逸！

2022-01-26

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

Ann Oncol:紫杉醇联合或不联合atezolizumab一线治疗不可切除、局部晚期或转移性三阴性乳腺癌的疗效: IMpassion131初次分析

2022-05-14

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

Clin Cancer Res：艾立布林联合帕博利珠单抗对转移性三阴性乳腺癌有效

2021-10-28

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

伦敦癌症研究所（ICR）：palbociclib有望治疗三阴性乳腺癌

2021-02-05

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

FDA批准吉利德的Trodelvy治疗三阴性乳腺癌

2021-06-19

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

欧盟人用药品委员会 (CHMP) 对sacituzumab govitecan单药治疗三阴性乳腺癌 (TNBC) 持积极意见

2021-10-21

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

AACR 2021：NX-1607治疗结直肠癌和三阴性乳腺癌，临床前研究效果显著

2021-08-08

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

NEJM：ADC药物Sacituzumab govitecan一线治疗转移性三阴性乳腺癌

2021-07-15

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

JAMA：卡培他滨维持治疗对早期三阴性乳腺癌疗效观察的影响

2021-08-11

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

Eur J Cancer：BRCA1/2突变对三阴性乳腺癌新辅助化疗时发生严重血液毒性风险的影响

2021-10-01

hb2008ye (审核中...)

前往app查看评论内容

#阴性乳腺癌#

Ann Oncol: atezolizumab联合白蛋白结合型紫杉醇一线治疗不可切除、局部晚期或转移性三阴性乳腺癌的疗效: IMpassion130最终总生存分析

2022-01-13

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

默沙东Keytruda治疗三阴性乳腺癌扩大标签申请未能获得FDA支持

2021-08-28

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

ASCO 2021：摘要概览与展望10 |乳腺癌研究概览（三阴性乳腺癌专栏）

2021-10-26

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

Cell Death Dis：FBI-1通过miR-30c/PXR通路增强三阴性乳腺癌的耐药性

2021-09-19

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

三阴性乳腺癌：令人闻风丧胆的肿瘤！3种新疗法或将提高生存率

2021-05-10

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

CSCO 2020丨袁芃教授：三阴性乳腺癌（TNBC）治疗未来之路----精准检测和新的靶点

2021-04-20

科室
- - 订阅+
  - 更多科室
工具
服务